Raphael Pharmaceutical (RAPH) Net Equity Issued and Repurchased (2022 - 2025)

Raphael Pharmaceutical (RAPH) has 4 years of Net Equity Issued and Repurchased data on file, last reported at $3000.0 in Q4 2025.

• For the quarter ending Q4 2025, Net Equity Issued and Repurchased changed N/A year-over-year to $3000.0; the trailing twelve-month figure through Dec 2025 stood at $243000.0 (down 13.21% YoY), and the FY2025 full-year result was $243000.0, down 13.21% from the prior year.
• Net Equity Issued and Repurchased eased to $3000.0 in Q4 2025, from $240000.0 in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $812000.0 in Q3 2023 to a low of $3000.0 in Q4 2025.
• A 4-year average of $209428.6 and a median of $112000.0 in 2022 frame the typical range for Net Equity Issued and Repurchased.
• Across the five-year window, Net Equity Issued and Repurchased soared 625.0% in 2023 and jumped 33.33% in 2025, its largest moves.
• Tracing RAPH's Net Equity Issued and Repurchased over 4 years: stood at $112000.0 in 2022, then tumbled by 83.04% to $19000.0 in 2023, then surged by 426.32% to $100000.0 in 2024, then plunged by 97.0% to $3000.0 in 2025.
• Business Quant data shows RAPH's Net Equity Issued and Repurchased at $3000.0 in Q4 2025, $240000.0 in Q1 2025, and $100000.0 in Q2 2024.